Novel antibody-based therapeutic agents targeting CD70: A potential approach for treating Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 90-93

  Law, Che Leung ^a   McEarchern, Julie ^a   Grewal, Iqbal ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity; Drug conjugate; Monoclonal antibodies; Paracrine growth loop; T cells; Waldenstr m

Indexed keywords

ALEMTUZUMAB; CD27 ANTIGEN; CD70 ANTIGEN; CYCLOPHOSPHAMIDE; DIFFERENTIATION ANTIGEN; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 24; MONOCLONAL ANTIBODY LD6; PREDNISONE; RITUXIMAB; SGN 70; SGN 75; TOSITUMOMAB I 131; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER THERAPY; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE; MEDICAL RESEARCH; NONHODGKIN LYMPHOMA; NONHUMAN; PARACRINE SIGNALING; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; WALDENSTROEM MACROGLOBULINEMIA; DRUG ANTAGONISM; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD70; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649556688     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.024     Document Type: Article

References (31)

1. Grewal IS. Overview of antibody-based therapeutics: present and future promise. In: Grewal IS, ed. Emerging Biotherapeutics. Boca Raton:CRC Press, FL; 2009:3-35.
2. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets 2008; 12:341-51.
3. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109:1185-92.
4. McEarchern JA, Smith LM, McDonagh CF, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008; 14:7763-72.
5. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006; 66:2328-37.
6. Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008; 14:6171-80.
7. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev 2003; 14:265-73.
8. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17:275-81.
9. Hendriks J, Gravestein LA, Tesselaar K, et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000; 1:433-40.
10. Arens R, Tesselaar K, Baars PA, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15:801-12.
11. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003; 4:49-54.
12. Takeda K, Oshima H, Hayakawa Y, et al. CD27-mediated activation of murine NK cells. J Immunol 2000; 164:1741-5.
13. Yang FC, Agematsu K, Nakazawa T, et al. CD27/CD70 interaction directly induces natural killer cell killing activity. Immunology 1996; 88:289-93.
14. Lens SM, Drillenburg P, den Drijver BF, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999; 106:491-503.
15. Baba M, Okamoto M, Hamasaki T, et al. Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. J Virol 2008; 82:3843-52.
16. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008; 112:4683-9.
17. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol 1996; 9:417-46.
18. Agathanggelou A, Niedobitek G, Chen R, et al. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995; 147:1152-60.
19. Hishima T, Fukayama M, Hayashi Y, et al. CD70 expression in thymic carcinoma. Am J Surg Pathol 2000; 24:742-6.
20. Chahlavi A, Rayman P, Richmond AL, et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res 2005; 65:5428-38.
21. Wischhusen J, Jung G, Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002; 62:2592-9.
22. Sawalha AH, Jeffries M, Webb R, et al. Defecive T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008; 9:368-78.
23. Diegmann J, Junker K, Loncarevic IF, et al. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006; 8:933-8.
24. Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007; 110:2537-44.
25. Aulwurm S, Wischhusen J, Friese M, et al. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006; 118:1728-35.
26. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007; 109:5096-103.
27. Dimopoulos MA, Anagnostopoulos A. Treatment of Waldenstrom's Macroglobulinemia. Curr Treat Options Oncol 2007; 8:144-53.
28. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7(suppl 5): S199-206.
29. Israel BF, Gulley M, Elmore S, et al. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther 2005; 4:2037-44.
30. Terrett JA, Pan C, Gangwar S, et al. CD70 antibody based drugs: two different mechanisms of action for the treatment of multiple cancer types. Proc Amer Assoc Cancer Res 2006; 47:(Abstract 1995).
31. Jeffrey SC, Nguyen MT, Moser RF, et al. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorg Med Chem Lett 2007; 17:2278-80.